10-K: QT Imaging Holdings Faces Delisting, Reports \$9 Million Loss in 2024

QT Imaging Holdings reports a \$9 million loss for 2024 and faces Nasdaq delisting, transitioning to the OTCQB Venture Market.

Summary

• QT Imaging Holdings, Inc. reports a net loss of \$9 million for the year ended December 31, 2024, compared to a \$6.1 million loss in 2023.
• The company's common stock faces delisting from The Nasdaq Global Market and has transitioned to the OTCQB Venture Market.
• Revenue increased significantly to \$4.88 million in 2024 from \$40,355 in 2023, primarily due to the sale of QT Breast Scanners.
• Operating expenses rose substantially, driven by increased research and development, selling, general, and administrative costs.
• The company has entered into a manufacturing agreement with Canon Medical Systems Corporation for QT Breast Scanners.
• QT Imaging is pursuing regulatory approvals and strategic partnerships to expand market access for its imaging technology.
• The company is developing new products, including an orthopedic scanner and an infant scanner, to expand its market opportunities.
• QT Imaging faces risks related to market acceptance of its products, competition, regulatory approvals, and the need for additional capital.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While revenue increased, the company is facing significant financial challenges, including a large net loss and delisting from Nasdaq. The future outlook is uncertain, and the company's ability to raise additional capital is a concern.

Positives

• Revenue increased significantly to \$4.88 million in 2024 from \$40,355 in 2023, driven by QT Breast Scanner sales.
• QT Imaging has entered into a manufacturing agreement with Canon Medical Systems Corporation for QT Breast Scanners.
• The company is developing new products, including an orthopedic scanner and an infant scanner, to expand its market opportunities.
• The company has approximately \$18 million in financial support from the U.S. National Institutes of Health.

Negatives

• QT Imaging Holdings reports a net loss of \$9 million for 2024, compared to a \$6.1 million loss in 2023.
• The company's common stock faces delisting from The Nasdaq Global Market and has transitioned to the OTCQB Venture Market.
• Operating expenses rose substantially, with research and development expenses increasing to \$3.27 million and selling, general, and administrative expenses increasing to \$11.55 million.
• The company has a working capital deficit of \$4.9 million as of December 31, 2024.

Risks

• The company faces risks related to market acceptance of its products, competition, regulatory approvals, and the need for additional capital.
• The company's reliance on third-party manufacturers and suppliers involves risks such as insufficient capacity, quality issues, and potential price increases.
• The company's debt agreements contain restrictions that may limit its flexibility in operating its business.
• The company is highly dependent on key members of its executive management team, and the loss of these individuals could impede its business plan.
• The company's common stock is now quoted on the OTCQB Venture Market tier, which is a volatile market that could depress the market price of its common stock.

Future Outlook

The company plans to expand its market presence, develop new products, and pursue regulatory approvals to drive future growth. Management believes that the cash received for the Lynrock Lake Term Loan and additional revenue anticipated from MOQs per the Amended Distribution Agreement will be sufficient to fund the Company's current operating plan for at least the next 12 months.

Industry Context

The medical imaging market is a large and growing market, with the global cancer screening market expected to reach approximately \$472 billion in 2033. The current standard of care for imaging in breast cancer screening, diagnosis, and treatment is far from satisfactory and may involve certain side effects. The company believes that its new technology can address the issues presented by these conventional imaging technologies with its accurate, safe, less expensive and easily deployable imaging systems.

Comparison to Industry Standards

• The ABUS segment is the largest and is expected to grow at a CAGR of 16% worldwide over the next five years, with more than 2,000 installations in place and a market value of \$850 million by 2024.
• The current standard of care for imaging in breast cancer screening, diagnosis, and treatment is far from satisfactory and may involve certain side effects.
• The knee is the most commonly injured joint by adolescent athletes with an estimated 2.5 million sports-related injuries presenting to emergency departments (EDs) annually.

Related Party Transactions

• The company has entered into various agreements with related parties, including Dr. John Klock and Lynrock Lake Master Fund LP.
• The company has entered into a Space and Equipment Sublease Agreement with the Practice, pursuant to which the Practice will sublease certain medical equipment and space, currently leased from Hamilton Landing Novato LLC by the Company, to the Practice for use in its operations, on a full-time and exclusive basis.

Stakeholder Impact

• Shareholders may experience dilution from future equity issuances.
• Employees may be affected by potential cost-cutting measures or changes in the company's strategic direction.
• Customers may benefit from the company's continued development of innovative imaging technologies.
• Creditors may be at risk if the company is unable to meet its debt obligations.

Next Steps

• The company intends to scale up its production by initially using CMSC, and may also look at strategic original equipment manufacturing (OEM) agreements for large production throughput.
• The Company intends to establish similar peer-review partnerships with respected medical organizations, practices, and practitioners in the future.

Key Dates

Keywords

QT Imaging, Breast Scanner, Medical Imaging, Canon Medical, NXC Imaging, Delisting, Financial Results, Regulatory Approvals, Product Development, Yorkville, Lynrock Lake, OTCQB